Earnings Labs

American Vanguard Corporation (AVD)

Q2 2018 Earnings Call· Tue, Aug 7, 2018

$2.82

-1.05%

Key Takeaways · AI generated
AI summary not yet generated for this transcript. Generation in progress for older transcripts; check back soon, or browse the full transcript below.

Same-Day

-1.95%

1 Week

-3.41%

1 Month

-1.22%

vs S&P

-1.93%

Transcript

Operator

Operator

Greetings and welcome to the American Vanguard Corporation’s Second Quarter 2018 Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, William Kuser, Director of Investor Relations. Thank you, sir. You may begin.

William Kuser

Analyst

Well, thank you very much, Jessie, and welcome everyone to American Vanguard’s second quarter and mid-year earnings review. Our speakers today will be Mr. Eric Wintemute, the Chairman and CEO of American Vanguard; Mr. David Johnson, the company’s Chief Financial Officer; and to assist in answering any questions you may have Mr. Bob Trogele, the company’s Chief Operating Officer. This afternoon, American Vanguard has filed the Form 10-Q with the SEC, for the quarter ended year providing additional details to the results that we will be discussing in this call. Let’s begin with our usual cautionary reminder. In today’s call, the company may discuss forward-looking information. Such information and statements are based on estimates and assumptions by the company’s management and are subject to various risks and uncertainties that may cause actual results to differ from management’s current expectations. Such factors can include weather conditions, changes in regulatory policy, competitive pressures and various other risks that are detailed in the company’s SEC reports and filings. All forward-looking statements represent the company’s best judgment as of the date of this call and such information will not necessarily be updated by the company. With that said, we turn the call over to Eric.

Eric Wintemute

Analyst

Thank you, Bill. Hello, everyone and welcome to our second quarter and mid-year 2018 earnings call. As always, thank you for your continued interest in American Vanguard. As per our press release, we reported strong financial results for the second quarter and first half of 2018. Net sales were up 39% for the quarter and 43% for the half year, and net income rose by 29% and 32% for the respective periods. I will let David give you a detailed analysis of our financial performance in a moment, but first, I want to give you a higher level perspective. Our gains in net sales for both periods were driven by the foreign acquisitions that we completed in the second half of 2017. As you may recall these include AgriCenter, a leading distributor in Central America. OHP, a specialty distributor serving the U.S. horticulture market; three domestic products, Parazone, a herbicide; Equus, a fungicide, and Abba, an insecticide; and a slate of products in Mexico. These deals which were obtained for reasonable consideration with no adverse impact to our borrowing capacity have proven to be sound investments. Further, we continue to demonstrate the ability to integrate new product lines into our global portfolio successfully. While new product sales are certainly a bright spot, there is more to our overall results. As business managers, we must also focus on changes in our performance in order to identify potential trends and assess the future health of the enterprise. During the second quarter and first half of 2018 for example, while we saw growth from our new products, we also experienced a modest decline in sales of existing product lines, as well as in overall gross margins. These are subjects deserving a further inquiry. First, let’s focus on how our existing product lines fared…

David Johnson

Analyst

Thank you, Eric. Good afternoon, everybody. As Bill mentioned, we filed our Form 10-Q for the three and six months ended June 30, 2018, just a few months ago. Everything I’m covering here is included in more detail in that document. With regard to the financial results, as Eric just detailed, the company’s sales for the second quarter of 2018 increased by 37%. Eric may have misstated the percentage at 39% a few months ago to $107 million as compared to sales of $78 million this time last year. Within that overall improvement, our international sales continued to grow in importance and represented 40% of the net sales in the second quarter as compared to 28% this time last year. Our first quarter gross margin ended at 40%, as Eric mentioned, this was in line with indications we gave last call. During the quarter, our operating expenses ended at 32% of net sales compared to 35% this time last year. On an absolute basis, operating expenses increased by 26% due to several factors. These include the expenses associated with the addition of newly acquired products and businesses, the build-out of our international structure and continued work to defend and develop our product portfolio. These increases were partially offset by lower incentive compensation accruals and a benefit of $1.5 million associated with the GAAP-required quarterly reassessment of the fair value of liabilities under the business purchase agreements completed in 2017. Our tax rate ended the quarter at 23%, which compared with 27% for the same period of the prior year, the reduced rate primarily driven by the introduction of the Tax Cuts and Jobs Act in December 2017. Overall, net income for the quarter increased by 30% to $5.6 million or $0.19 per share as compared to $4.3 million or $0.15…

Eric Wintemute

Analyst

Thank you, David. We have all heard news accounts of the extreme measures being taken by the central government of China against chemical manufacturing plants, citing noncompliance with environmental laws. Numerous facilities have been closed or have their operations suspended suddenly and without warning. These actions have affected our entire industry, including not only production facilities within China, but also plants throughout the world who depend upon them. To date, thanks to the efforts of our supply chain team, we have been able to minimize supply disruptions. Nevertheless, we continue to monitor this matter closely, while developing relationships throughout the globe to mitigate the risks of sourcing key materials from any one country. Further, we are regularly communicating the ever-changing sourcing dynamics with our sales and marketing team globally, so that we can ensure we have the right inventory at the lowest possible cost. In addition, the plant closures if undoubtedly heard extensive news coverage of the trade war between U.S. and China. We have seen tariffs and retaliatory tariffs imposed by both sides on various products, ranging from metals to sorghum to chemicals. It is often not possible to predict, which product will be targeted next. However, we continue to monitor closely the United States Trade Representative, which on August 2, floated the idea of increasing a proposed duty on Chinese sourced chemicals, including crop inputs and intermediates from 10% to 25%. It is uncertain whether or when this duty may be imposed, but we can say that such a duty would affect the cost of goods for our industry, which in turn would likely lead to price increases. Now let’s turn from China and towards the current environment for acquisitions. As we reported in our last call, we continue to see businesses and product lines being divested in…

Operator

Operator

Thank you. [Operator Instructions] Our first question is coming from the line of Joseph Reagor with Roth Capital Partners. Please proceed with your questions.

Joseph Reagor

Analyst

Good afternoon guys and thanks for taking the questions. Two things, I guess, first one, some of your margins improved during the quarter, it sounded like, because of increased usage of your factories. And when I look at the balance sheet, the inventory level increased a decent bit during the quarter. Did that play a role in those factory efficiencies? And is that an intentional build of inventory ahead of the third quarter?

Eric Wintemute

Analyst

Probably to a smaller degree. I think our inventory build was on some of the newer products that we acquired and the timing of bringing those in from China. That’s probably the bulk of it.

Joseph Reagor

Analyst

Okay. And so you don’t feel like that really impacted the factory efficiency during the quarter?

Eric Wintemute

Analyst

We have scheduled and run, I think – we probably, maybe run a little bit more of our Folex than we might have at the beginning of the year. I’m thinking about it. But now I think typically, second quarter and third quarter are both relatively strong quarters for production, particularly for metam sodium, our soil fumigant, which there’s a substantial amount of product that goes into third and fourth quarter. And we have to position that throughout the United States.

Joseph Reagor

Analyst

Okay, fair enough. And then, on the insecticide segment, sales climbed about 17% or so year-on-year. Can you give us a little bit more color on what drove that? Was it some timing last year that was different this year? Or were there specific products where you saw some competitive pressures or full inventory channels?

Eric Wintemute

Analyst

Let me take a look here. Where are we as far as our insecticides? So we’re talking about the growth here. So I’m just trying to think. So I’m looking at insecticides. Let’s see. Yes, this is driven in the granular stuff. So our regular insecticides are off slightly. As we break out granular insecticides, let’s see. Yes, those are also down. So yes, I’ve got our insecticides down here. What numbers are you looking at, Joseph?

Joseph Reagor

Analyst

So I was looking at $39.4 million in 2Q 2017 versus $32.7 million in 2Q of this year.

David Johnson

Analyst

He’s talking about it being down.

Eric Wintemute

Analyst

Oh, being down. I thought you – yes. No, I thought you were saying that we were up. We’re down.

David Johnson

Analyst

All right. Got it.

Eric Wintemute

Analyst

Yes. Got it. Okay. So, yes, Bidrin is our cotton insecticide. That was down primarily. It’s got two new seasons. It was the early season, which is kind [indiscernible] and then the bug pressures in the second half, and it’s kind of the third quarter. I think we mentioned that Thimet was down as peanut acreage was down in that 20% to 30%. And then, Aztec, which is more of a timing issue. There’s a relative sizable sale into Korea that happened in the second quarter of the last – this year – I mean last year that will happen in the third quarter of this year. So those are probably the drivers there.

Joseph Reagor

Analyst

Okay. Thank you. I’ll turn it over.

Operator

Operator

Thank you. Our next question is coming from the line of Chris Kapsch with Loop Capital. Please proceed with your question.

Chris Kapsch

Analyst

Hey, good afternoon, guys. I had a follow-up question on the commentary around Impact. And last year, I think it was – you characterized that particular product or business as it’s seen sort of intensified competitive pressures. And now this year, despite sort of a tough backdrop for corn, you’re seeing higher sales. So, I’m just wondering if – what the driver is there. Has the competitive dynamic changed? Or is this just the function of perhaps a more pronounced resistant situation with glyphosate? Or anything else going on there?

Eric Wintemute

Analyst

Well, I think the key to this was getting the price reduction down, which again, you may remember in the third quarter last year, we took down the price and in fact, credited material that was in the channel to trade. So I think we feel a little more stable with the pricing today and, I think, responded well in the marketplace because of it. Bob?

Bob Trogele

Analyst

Yes. Thanks. Hi, Chris. We also had a delayed planting season. It was very wet in April, May. And therefore, the fields were just, I would say, more dirty at the end of the season, which fits very well into Impact. And then we also launched a new solution into that segment called ImpactZ, which was received very well by the trade. So that’s what drove it.

Chris Kapsch

Analyst

I see. That’s helpful. And then just maybe, you could just comment more generally about sort of the backdrop that you described, particularly as there’s presumably a lot of crop chemical folks having issues with sourcing active ingredients out of China, and yet in North America, you have somewhat challenged farmers at least for some of the cash grow crop. So I’m wondering, is that resulting in any sort of dislocations that you can leverage to your advantage? Is it changing the competitive dynamic? I mean you mentioned the idea of having to raise prices. I think you’re talking about the industry more generally. But there’s a time when I’m not sure the growers are enthused about paying more further input. So maybe if you can just talk about how that – how you see the competitive dynamic evolving against that backdrop. Thanks.

Eric Wintemute

Analyst

So we’ve – it varies by product. I mean, some products are in an extremely tight supply and have doubled or even tripled in cost. Others, there have been an abundance, and we’ve seen some products actually decrease. But we need – a normal duty out of China is in that 6.5%. When you talk about, the talk was to move it to 16.5%, and now the talk is to move it to 31.5%. And those types of increases are not – we don’t anticipate we’re going to bear them. So whether we put through a tariff surcharge, which may make more sense in a volatile trade war, but in some manners, things have to change, and then consumers will have to decide what they want to put in place.

Chris Kapsch

Analyst

Has any of the dislocation resulted in opportunities for you guys to, say, pick up either pricing or even share, I guess, as some of the competitive – competitor products may have insufficient supplies of the intermediates?

Eric Wintemute

Analyst

Yes, it does. We’re looking at replacement costs, and in some cases, we’ve moved prices up, knowing that there will be a period of time for inventories in the market to clear rather than to try to compete now, when we know something is just going to get more expensive. So we’ve – in some cases, yes, we’ve moved prices up and we’re – and that’s one of the reasons why we do have a little bit more inventory, because we’re anticipating future supplies to be increased as far as cost.

Chris Kapsch

Analyst

Okay. Thanks for the extra color.

Operator

Operator

Thank you. [Operator Instructions]. Our next question is coming from the line of Jim Sheehan with SunTrust. Please proceed with your question.

Pete Osterland

Analyst

Good afternoon this is Pete on for Jim.

Eric Wintemute

Analyst

Hi, Pete.

Pete Osterland

Analyst

Have you seen an impact from a shift in the global mix between corn and soybean acreage? And what is your overall outlook for corn product volumes?

Bob Trogele

Analyst

I would say – hi, Pete. this is Bob. I would just say that there have to be soybean growers that are disappointed with the high price going into the spring market. We saw an increase in soybean acres, as you saw. I think we’re going to probably see a shift – a slight shift back to corn for the coming season. But again, all the talk about the China tariffs on soybeans, you have to be able to shift your supply situation elsewhere, meaning down to Brazil and down to Argentina. And one would question whether or not you can do that in the short-term. So, I would say in the midterm, if the trade war continues, then you’ll see a shift further to South America away from soybeans, which would then favor corn growing in the United States. And sadly enough, that would favor us, because we’re probably – I said our portfolio, is more focused in corn, and I’m saying that sarcastically. So more corn on corn, better for CSIs and for our herbicides. But we are all trying to build our soybean portfolio, but we’re such a small player, so we can only really gain either way. So, that’s kind of our view of things. But I think it’s too early to make the call as far as major shifts.

Pete Osterland

Analyst

All right, great. Thanks. Are you seeing any negative margin impact from rising freight and logistics costs in the U.S?

Eric Wintemute

Analyst

We are. We’ve definitely seen – I mean there’s a shortage of – I think the 188,000 truck drivers in the United States. And then if you go towards hazardous freight, which some of our freight is, those become even more difficult. So, just getting trucks is a real challenge. Our team has done a fantastic job. We haven’t had any major disruptions to deliveries of anything, and our customer service and, again, logistics department, have done a great job to secure the freight that we need. And I think maybe we had some challenges last year during the hurricane when we’d get calls from the government and say, can you have this delivery here by – calling at 4 o’clock – can you have it here by 9 a.m. the next morning, 600 miles away? So, those kind of challenges are there. But definitely, we’re seeing increases in the freight costs.

Pete Osterland

Analyst

All right. Thank you.

Operator

Operator

Thank you. The next question is a follow-up coming from the line of Joseph Reagor with Roth Capital Partners. Please proceed with your questions.

Joseph Reagor

Analyst

Hey guys, just add one more for you. Following the announced sale of Arysta by Platform, do you think there’s going to be any opportunities to do like what you have done before and buy some of the – let’s call it, duplicate product lines there?

Eric Wintemute

Analyst

Certainly, there is that possibility. We’ve – I mean I think that deal has to go through. But there are definitely overlapping chemistries there. I don’t know that there’s going to be forced divestitures, but there could be, and Bob have, your thoughts?

Bob Trogele

Analyst

Yes. I think, if there maybe one or two forced divestitures, but I think probably, one of the things they’re going to be looking at is maybe looking at their portfolio of breadth, because Arysta had quite a few active ingredients. UPL has quite a few active ingredients. So, I think that will probably sort itself out after they get the FTC approval. We don’t really see any major FTC issues for them in the U.S., but that’s for the FTC to call.

Joseph Reagor

Analyst

Okay. But fair to say that if there’s any opportunities there, you’ll have a look like you usually do?

Bob Trogele

Analyst

Yes.

Joseph Reagor

Analyst

Okay. Thanks guys.

Operator

Operator

Thank you. The next question is a follow-up coming from the line of Chris Kapsch with Loop Capital. Please proceed with your question.

Chris Kapsch

Analyst

Yes. Also, along the lines of M&A, but curious about given the shifts in the macro backdrop, with the commodity prices coming down, with all this uncertainty about tariffs and the implications, the supply chain challenges and so forth, is that translating into maybe, a more willingness on behalf of any would-be sellers than there might have been prior and therefore creating an opportunity for you? Or is it too early to see any sort of change in willingness or even the expectations in terms of transaction values?

Bob Trogele

Analyst

I would say Chris, that’s too early to say, because a lot of the deals are still, I would say, in transition, meaning the merger is happening. Two, there are still ones, which are not settled, like the UPL-Arysta one by the FTC. I would say probably more so on the manufacturing side, we may in future, have opportunities to produce more things in the United States as – and we’ll probably bring in more raw materials, and maybe – as you know, our company can sympathize, but that’s too early to say. It really depends on how this plays out with the China trade deal that is going to come or not come.

Chris Kapsch

Analyst

Fair enough. We’ll keep tabs. Thanks.

Operator

Operator

Thank you. [Operator Instructions]. Thank you. It appears we have no additional questions at this time. So, I’d like to pass the floor back over to Mr. Wintemute for any additional concluding comments.

Eric Wintemute

Analyst

Thank you. And on behalf of everybody here at American Vanguard, we appreciate your time and attention to our call and look forward to updating you with more news in the future. Thank you very much.

Operator

Operator

Ladies and gentlemen, this does conclude today’s teleconference. We thank you for your participation. You may disconnect your lines at this time.